Proton-pump inhibitors adverse effects: a review of the evidence and position statement by the Sociedad Española de Patología Digestiva
Open accessAbstract
INTRODUCTION: In the last few years a significant number of papers have related the use of proton-pump inhibitors (PPIs) to potential serious adverse effects that have resulted in social unrest. OBJECTIVE: The goal of this paper was to provide a literature review for the development of an institutional position statement by Sociedad Española de Patología Digestiva (SEPD) regarding the safety of long-term PPI use. MATERIAL AND METHODS: A comprehensive review of the literature was performed to draw conclusions based on a critical assessment of the following: a) current PPI indications; b) vitamin B12 deficiency and neurological disorders; c) magnesium deficiency; d) bone fractures; e) enteric infection and pneumonia; f) interactions with thienopyridine derivatives; e) complications in cirrhotic patients. RESULTS: Current PPI indications have remained unchanged for years now, and are well established. A general screening of vitamin B12 levels is not recommended for all patients on a PPI; however, it does seem necessary that magnesium levels be measured at therapy onset, and then monitored in subjects on other drugs that may induce hypomagnesemia. A higher risk for bone fractures is present, even though causality cannot be concluded for this association. The association between PPIs and infection with Clostridium difficile is mild to moderate, and the risk for pneumonia is low. In patients with cardiovascular risk receiving thienopyridines derivatives it is prudent to adequately consider gastrointestinal and cardiovascular risks, given the absence of definitive evidence regardin potential drug-drug interactions; if gastrointestinal risk is found to be moderate or high, effective prevention should be in place with a PPI. PPIs should be cautiously indicated in patients with decompensated cirrhosis. CONCLUSIONS: PPIs are safe drugs whose benefits outweigh their potential side effects both short-term and long-term, provided their indication, dosage, and duration are appropriate.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Long-term use of PPIs exposes patients to an increased risk of developing extra-intestinal disorders.
“The use of PPIs is generally well tolerated, although their long-term use exposes patients to an increased risk of developing extra-intestinal disorders[6-8]”
From Proton pump inhibitors and dysbiosis: current knowledge and aspects to be clarified (2019) · cites this paper as [7]
The citation lists haven’t been fetched yet
References 162 · Cited by 54
- Authors
- de la Coba Ortiz, C., Argüelles Arias, F., Martín de Argila de Prados, C., Júdez Gutiérrez, J., Linares Rodríguez, A., Ortega Alonso, A., Rodríguez de Santiago, E., Rodríguez-Téllez, M., Vera Mendoza, M. I., Aguilera Castro, L., Álvarez Sánchez, Á., Andrade Bellido, R. J., Bao Pérez, F., Castro Fernández, M., & Giganto Tomé, F.
- Affiliations
- Hospital Universitario Virgen Macarena (ES)
- Venue
- Revista Española de Enfermedades Digestivas
- Published
- 2016
- Volume
- 108
- Issue
- 4
- Pages
- 207-224
- ISSN
- 1130-0108 (ISSN-L)
- OpenAlex
- W2344692790
- Cited by
- 54
- References
- 162
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 2 · 2023: 4 · 2022: 3 · 2021: 3 · 2020: 5 · 2019: 7 · 2018: 10 · 2017: 14 · 2016: 1
- FWCI
- 11.63
- Type
- journal article
- Language
- es
- Open access
- green
- idus.us.es
- Licence
- cc-by-nc-nd
- Locations
- Revista Española de Enfermedades Digestivas (publishedVersion)
- PubMed (publishedVersion)
- idUS (Universidad de Sevilla) (submittedVersion, cc-by-nc-nd)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Scientific Electronic library online (Sciences Carlos III Health Institute) (submittedVersion)
- RISalud Institutional Health Repository of Andalucía (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Gastroenterology › Gastroesophageal reflux and treatments
- Health Sciences › Medicine › Geriatrics and Gerontology › Pharmaceutical Practices and Patient Outcomes
- Health Sciences › Medicine › Surgery › Helicobacter pylori-related gastroenterology studies
- Keywords
- proton pump inhibitors, adverse drug reactions, long-term PPI use, vitamin B12 deficiency, hypomagnesemia, bone fractures, Clostridium difficile infection, pneumonia, decompensated cirrhosis, drug safety
- MeSH terms
- Drug Interactions, Humans, Infections, Liver Cirrhosis, Magnesium Deficiency, Nervous System Diseases, Evidence-Based Medicine, Fractures, Bone, Proton Pump Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review